Skip to main content

Volume 14 Supplement 3

Integrase Inhibitors

Review

Edited by N Zöllner

  1. Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase. In October 2007, the...

    Authors: Jean-François Mouscadet and Luba Tchertanov
    Citation: European Journal of Medical Research 2009 14(Suppl 3):5
  2. Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug re...

    Authors: F Cossarini, A Castagna and A Lazzarin
    Citation: European Journal of Medical Research 2009 14(Suppl 3):22
  3. Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also ...

    Authors: Margaret Johnson
    Citation: European Journal of Medical Research 2009 14(Suppl 3):43
  4. Similar to all antiretroviral drugs, failure of raltegravirbased treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug. HIV resistance to...

    Authors: François Clavel
    Citation: European Journal of Medical Research 2009 14(Suppl 3):47

Annual Journal Metrics

  • 2022 Citation Impact
    4.2 - 2-year Impact Factor
    3.6 - 5-year Impact Factor
    1.120 - SNIP (Source Normalized Impact per Paper)
    0.812 - SJR (SCImago Journal Rank)

    2023 Speed
    47 days submission to first editorial decision for all manuscripts (Median)
    151 days submission to accept (Median)

    2023 Usage
    1,790,363 downloads
    5,415 Altmetric mentions